Conditioning regimens for elderly AML patients receiving haplo-HSCT

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In elderly patients with AML, transplantation can improve long-term survival but carries high treatment-related risk. This randomized trial compares two conditioning regimens before haplo-HSCT to see if reducing toxicity lowers mortality. The study builds on prior single-arm data suggesting Bu/Flu/Cy/ATG may be safer and seeks prospective evidence. Eligible participants are adults 55 and older in first complete remission with a haploidentical donor. Outcomes include transplant-related mortality and safety profiles between regimens.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- (a)Diagnosed with AML in first complete remission (CR1). (b)Age ≥55 years. (c)Availability of an haploidentical donor, first transplant, no matched sibling or unrelated donor.

(d)Willingness to provide written informed consent.

Exclusion Criteria:

* (a) Uncontrolled active infection. (b) Secondary AML. (c)Refusal to provide informed consent.

Where it's running

• Peking University People's Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Yuqian Sun
• Email: sunyuqian83@hotmail.com
• Phone: 861088326666

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• CRD3874-SI in People with Leukemia

  A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07661095

• Allogeneic CAR-T CT0890B for relapsed/refractory AML

  This study tests whether a universal CAR-T cell therapy called CT0890B is safe and potentially effective for adults with relapsed or refractory acute myeloid leukemia who express NKG2D ligands.

  Recruiting Phase 1 Peking University People's Hospital · Beijing · NCT07617285

• Biomarkers in Bone Marrow to Predict AML Chemosensitivity

  This study tests whether markers in bone marrow can predict how adults with AML will respond to chemotherapy.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07587944

• Azacitidine plus venetoclax maintenance vs azacitidine alone in AML

  This trial tests whether adding venetoclax to azacitidine maintenance helps people with AML stay disease-free after achieving first remission.

  Recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07539818

• Azacitidine with APG1252 in high-risk AML (Phase 1b/2)

  This study tests whether adding APG1252 to azacitidine is safe and helps some patients with high-risk AML feel better or respond to treatment.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07508982

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.